Ramucirumab is a human immunoglobulin G1 monoclonal antibody that binds to VEGFR-2 and is used to treat metastatic and/or inoperable gastric, colorectal, and non-small cell lung cancer. The gene discussed is KDR; the disease is non-small cell lung carcinoma.